Clinical Trial Update: The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical program evaluating HRS8179 for severe cerebral edema after large hemispheric infarction is currently recruiting, sponsored by Beijing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• HRS8179

Snippet

Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Conditions: Severe Cerebral Edema Following Large Hemispheric Infarction | Phase 2, Phase 3 | Status: RECRUITING